Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-14 5:28 pm Purchase | 13G | Syros Pharmaceuticals Inc. SYRS | Avidity Partners Management LP | 2,857,573 9.900% | 195,367 (+7.34%) | View |
| 2024-11-14 5:24 pm Purchase | 13G | Syros Pharmaceuticals Inc. SYRS | Bain Capital Life Sciences Fund II L.P. | 2,750,151 11.000% | 343 (+0.01%) | View |
| 2024-11-14 5:05 pm Sale | 13G | Syros Pharmaceuticals Inc. SYRS | Blue Owl Capital Holdings LP | 515,855 1.920% | -977,397 (-65.45%) | View |
| 2024-11-12 4:30 pm Purchase | 13G | Syros Pharmaceuticals Inc. SYRS | Invus Global Management LLC | 3,651,201 9.900% | 82,359 (+2.31%) | View |
| 2024-08-02 6:39 pm Purchase | 13G | Syros Pharmaceuticals Inc. SYRS | Invus Global Management LLC | 3,568,842 9.900% | 3,568,842 (New Position) | View |
| 2024-02-14 8:56 pm Purchase | 13G | Syros Pharmaceuticals Inc. SYRS | Blue Owl Capital Holdings LP | 1,493,252 5.740% | 1,493,252 (New Position) | View |
| 2024-02-13 8:22 pm Purchase | 13G | Syros Pharmaceuticals Inc. SYRS | Avidity Partners Management LP | 2,662,206 9.900% | 472,487 (+21.58%) | View |
| 2024-02-13 7:02 pm Sale | 13G | Syros Pharmaceuticals Inc. SYRS | Ally Bridge MedAlpha Master Fund L.P. | 570,976 2.600% | -868,403 (-60.33%) | View |
| 2024-02-13 6:59 pm Purchase | 13G | Syros Pharmaceuticals Inc. SYRS | Bain Capital Life Sciences Fund II L.P. | 2,749,808 11.000% | 625,114 (+29.42%) | View |
| 2024-02-09 5:08 pm Purchase | 13G | Syros Pharmaceuticals Inc. SYRS | Artal International S.C.A. | 3,568,842 9.900% | 2,105,013 (+143.80%) | View |
| 2024-02-07 07:09 am Purchase | 13G | Syros Pharmaceuticals Inc. SYRS | ADAGE CAPITAL PARTNERS GP L.L.C. | 2,623,984 9.990% | 1,370,156 (+109.28%) | View |
| 2024-01-02 4:15 pm Purchase | 13G | Syros Pharmaceuticals Inc. SYRS | Point72 Asset Management L.P. | 1,471,771 5.700% | 1,471,771 (New Position) | View |
| 2023-12-26 5:19 pm Purchase | 13D | Syros Pharmaceuticals Inc. SYRS | Samsara BioCapital L.P. | 2,515,523 9.500% | 909,977 (+56.68%) | View |
| 2023-10-20 4:15 pm Purchase | 13D | Syros Pharmaceuticals Inc. SYRS | Samsara BioCapital L.P. | 1,605,546 7.500% | 1,605,546 (New Position) | View |
| 2023-02-14 4:07 pm Purchase | 13G | Syros Pharmaceuticals Inc. SYRS | Avidity Partners Management LP | 2,189,719 9.900% | 69,719 (+3.29%) | View |
| 2023-02-14 06:15 am Purchase | 13G | Syros Pharmaceuticals Inc. SYRS | Bain Capital Life Sciences Fund II L.P. | 2,124,694 11.000% | 2,124,694 (New Position) | View |
| 2023-02-10 7:41 pm Sale | 13G | Syros Pharmaceuticals Inc. SYRS | Artal International S.C.A. | 1,463,829 7.200% | -2,036,171 (-58.18%) | View |
| 2023-01-27 6:01 pm Purchase | 13G | Syros Pharmaceuticals Inc. SYRS | Ally Bridge MedAlpha Master Fund L.P. | 1,439,379 6.900% | 1,439,379 (New Position) | View |
| 2023-01-25 5:00 pm Purchase | 13G | Syros Pharmaceuticals Inc. SYRS | ADAGE CAPITAL PARTNERS GP L.L.C. | 1,253,828 6.040% | 1,253,828 (New Position) | View |
| 2022-11-10 11:55 am Purchase | 13G | Syros Pharmaceuticals Inc. SYRS | FMR LLC | 104,614 0.516% | 104,614 (New Position) | View |